The American Journal of Medicine
Volume 111, Issue 8 , Pages 607-613, 1 December 2001

Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome

  • Richard S Legro, MD

      Affiliations

    • Department of Obstetrics and Gynecology (RSL), Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA
  • ,
  • Allen R Kunselman, MA

      Affiliations

    • Department of Health Evaluation Sciences (ARK), Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA
  • ,
  • Andrea Dunaif, MD

      Affiliations

    • Corresponding Author InformationRequest for reprints should be addressed to Andrea Dunaif, MD, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Medical School, 303 East Chicago Avenue, Tarry 15-709, Chicago, Illinois 60611-3008 USA
    • Division of Women’s Health (AD), Departments of Medicine and Obstetrics and Gynecology, Brigham and Women’s Hospital, Boston, Massachusetts, USA

Received 15 November 2000; accepted 31 July 2001.

Abstract 

Purpose

Women with polycystic ovary syndrome are hyperandrogenemic and insulin resistant, which are associated with alterations in circulating lipid and lipoprotein levels. We sought to determine the prevalence of, and risk factors for, lipid abnormalities in these women.

Subjects and methods

Non-Hispanic white women with polycystic ovary syndrome (n = 195) and ethnically matched control women (n = 62) had fasting blood obtained for hormone and lipid levels. Subjects were categorized by body mass index (nonobese <27 kg/m2, obese ≥27 kg/m2), and analyses were adjusted for age.

Results

Total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels increased significantly in obese women with polycystic ovary syndrome (n = 153) compared with obese control women (n = 35; mean difference in total cholesterol level = 29 mg/dL; 95% confidence interval [CI]: 14 to 45 mg/dL; P <0.001; mean difference in LDL-C level = 16 mg/dL; 95% CI: 4 to 30 mg/dL; P = 0.006). Similarly, total cholesterol and LDL-C levels increased significantly in nonobese women with polycystic ovary syndrome (n = 42) compared with nonobese control women (n = 27; mean difference in total cholesterol = 32 mg/dL; 95% CI: 13 to 52 mg/dL; P <0.001; mean difference in LDL-C level = 32 mg/dL; 95% CI: 15 to 52 mg/dL; P <0.001). In obese women, high-density lipoprotein cholesterol (HDL-C) and triglyceride levels increased significantly in women with polycystic ovary syndrome compared with control women (mean difference in HDL-C level = 6 mg/dL; 95% CI: 2 to 12 mg/dL; P = 0.002; mean difference in triglyceride level = 34 mg/dL; 95% CI: 1 to 77 mg/dL; P = 0.04). Differences in LDL-C and HDL-C levels, but not triglyceride levels, remained significant after adjusting for alcohol intake, smoking, and exercise. Although age, body mass index, and polycystic ovary syndrome status were significant predictors of lipid levels, these factors accounted for no more than 25% of the variance.

Conclusions

In this large study of non-Hispanic white women, elevations in LDL-C levels were the predominant lipid abnormality in women with polycystic ovary syndrome, independent of obesity. The characteristic dyslipidemia of insulin resistance was absent. Indeed, obese women with polycystic ovary syndrome had relatively elevated HDL-C levels, which may confer some protection against cardiovascular disease.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by Grants DK 40605, HD 0118, HD 34449, RR 10732, and RR 02635 from the National Institutes of Health.

PII: S0002-9343(01)00948-2

The American Journal of Medicine
Volume 111, Issue 8 , Pages 607-613, 1 December 2001